MAPK3 and prostate carcinoma: Furthermore, Zhang et al. demonstrated that EGF, acting through the ERK1/2 pathway, induced the degradation of EPLIN, subsequently impacting the invasiveness of prostate cancer cells and epithelial–mesenchymal transition [61].